Holen Sie sich die Stockscreener-App
0.358
4.07%
0.014
Vorhandelsmarkt:
.37
0.012
+3.35%
Schlusskurs vom Vortag:
$0.344
Offen:
$0.341
24-Stunden-Volumen:
703.81K
Relative Volume:
0.85
Marktkapitalisierung:
$17.77M
Einnahmen:
$1.38M
Nettoeinkommen (Verlust:
$-179.05M
KGV:
-0.0583
EPS:
-6.14
Netto-Cashflow:
$-155.03M
1W Leistung:
+0.36%
1M Leistung:
+4.99%
6M Leistung:
-69.40%
1J Leistung:
-86.07%
1-Tages-Spanne:
$0.3401
$0.3665
1-Wochen-Bereich:
$0.325
$0.3665
52-Wochen-Spanne:
$0.3001
$4.17
Bioxcel Therapeutics Inc Stock (BTAI) Company Profile
Firmenname
Bioxcel Therapeutics Inc
Sektor
Branche
Telefon
203-643-8060
Adresse
555 LONG WHARF DRIVE, NEW HAVEN, CT
Vergleichen Sie BTAI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BTAI
Bioxcel Therapeutics Inc
|
0.358 | 17.77M | 1.38M | -179.05M | -155.03M | -6.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-02-21 | Herabstufung | UBS | Buy → Neutral |
| 2023-08-15 | Herabstufung | Mizuho | Buy → Neutral |
| 2023-07-17 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-03-10 | Herabstufung | Jefferies | Buy → Hold |
| 2022-12-01 | Hochstufung | Goldman | Sell → Neutral |
| 2022-07-07 | Eingeleitet | Mizuho | Buy |
| 2022-04-06 | Bestätigt | BofA Securities | Buy |
| 2021-11-15 | Herabstufung | Goldman | Neutral → Sell |
| 2021-04-09 | Eingeleitet | Berenberg | Buy |
| 2021-02-01 | Eingeleitet | UBS | Buy |
| 2020-10-30 | Eingeleitet | Goldman | Buy |
| 2020-09-02 | Eingeleitet | Jefferies | Buy |
| 2020-08-17 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-04 | Eingeleitet | Guggenheim | Buy |
| 2020-04-01 | Eingeleitet | BofA/Merrill | Buy |
| 2020-02-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-08 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
Alle ansehen
Bioxcel Therapeutics Inc Aktie (BTAI) Neueste Nachrichten
Why BioXcel Therapeutics Shares Are Rising Tuesday - MSN
BioXcel Therapeutics expands board, appoints new director - MSN
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Sees Large Drop in Short Interest - Defense World
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Shares Sold by Jane Street Group LLC - Defense World
Bioxcel Therapeutics Appoints Dr. Rajiv Patni to Board - TipRanks
Thinking about buying stock in Hanryu Holdings, Absci Corp, Spero Therapeutics, BioXcel Therapeutics, or Cybin? - Marketscreener.com
BioXcel Therapeutics files to sell 5.1M shares of common stock by selling shareholders - MSN
BioXcel Therapeutics Amends Employment Agreements for Executives - Defense World
BioXcel Therapeutics (NASDAQ:BTAI) Earns “Underperform” Rating from Bank of America - Defense World
BioXcel Therapeutics amends executive compensation - Investing.com
BioXcel Therapeutics amends executive compensation By Investing.com - Investing.com UK
Top execs at New Haven-based BioXcel face compensation reductions amid company’s financial struggles - Hartford Business Journal
Are Investors Keen On Selling Holdings In BioXcel Therapeutics Inc (NASDAQ: BTAI)? - Stocks Register
Bioxcel Therapeutics Revises Executive Compensation Structure - TipRanks
BioXcel Therapeutics (NASDAQ:BTAI) Price Target Lowered to $5.00 at Canaccord Genuity Group - Defense World
State Street Corp Sells 47,600 Shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) - Defense World
BioXcel Therapeutics (BTAI) Moves to Buy: Rationale Behind the Upgrade - MSN
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Shares Sold by BNP Paribas Financial Markets - Defense World
Bioxcel therapeutics CEO sells shares worth $1,131 By Investing.com - Investing.com South Africa
Bioxcel therapeutics CFO Richard Steinhart sells $206 in stock By Investing.com - Investing.com Nigeria
Bioxcel therapeutics executive sells $153 in stock By Investing.com - Investing.com Australia
Bioxcel therapeutics' chief scientific officer sells $151 worth of stock By Investing.com - Investing.com Canada
Bioxcel therapeutics CFO Richard Steinhart sells $206 in stock - Investing.com India
Bioxcel therapeutics executive sells $153 in stock - Investing.com
Bioxcel therapeutics CEO sells shares worth $1,131 - Investing.com
Bioxcel therapeutics exec sells $58 in stock By Investing.com - Investing.com UK
BioXcel Therapeutics stock hits 52-week low at $0.35 - Investing.com India
BioXcel Therapeutics stock hits 52-week low at $0.35 By Investing.com - Investing.com Nigeria
BioXcel Therapeutics (STU:BX2) 5-Day RSI : 7.74 (As of Dec. 05, 2024) - GuruFocus.com
BioXcel Therapeutics stock hits 52-week low at $0.4 By Investing.com - Investing.com Canada
BioXcel Therapeutics stock hits 52-week low at $0.4 - Investing.com India
BioXcel Therapeutics announces pricing of $7M public offering - MSN
BioXcel Therapeutics stock hits 52-week low at $0.5 By Investing.com - Investing.com Australia
BioXcel Therapeutics Prices of $7 Million Public Offering - citybiz
BioXcel Therapeutics stock hits 52-week low at $0.5 - Investing.com India
BioXcel Therapeutics announces $7M public offering - Hartford Business Journal
BioXcel Prices New Offering - Baystreet.ca
BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering - GlobeNewswire
BioXcel Therapeutics Announces $7M Public Offering at $0.48 Per Share with Warrants | BTAI Stock News - StockTitan
Finanzdaten der Bioxcel Therapeutics Inc-Aktie (BTAI)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):